Speeding innovation for industry
Success | Diagnosis and innovative treatment
Fluoptics’ fluorescent tracers are used with the Fluobeam® imaging system to highlight details like tissue vascularization, blocked veins, and tumor edges to within 300 microns’ accuracy—a boon to surgeons.
Fluoptics, founded in 2009, works with Leti through annual research contracts. The company uses the lab’s physics, optics, and chemistry equipment and leverages its indepth knowledge of medical instrumentation.
Fluoptics combines fluorescence imaging with a variety of tracers capable of following the vessels of the lymphatic circulation system and targeting tumor cells, for instance. Surgeons can now see the edges of a tumor with unparalleled precision and observe biological events previously invisible to the naked eye. Fluoptics has integrated this technology into portable, cost-effective systems that are easy to use in actual operating room conditions.
Fluoptics’ imaging systems are designed for use in cancer, cardiovascular, liver, and reconstructive surgery. The Grenoble-based company has also opened an office in Boston, MA to serve the US market.
Resources and skills
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.